Risperdal Lawyers at Bernstein Liebhard LLP Look Ahead to June Meeting in Pennsylvania Mass Tort Program

Share Article

The Firm is representing Risperdal lawsuit plaintiffs who allegedly experienced gynecomastia, or male breast growth, due to their use of the antipsychotic medication.

Free Case Review
Our Firm is representing Risperdal plaintiffs who allegedly experienced excessive male breast development as a result of treatment with this medication.

A Pennsylvania Court overseeing hundreds of Risperdal lawsuits (http://www.risperdallawsuit2014.com/), including numerous claims filed over the antipsychotic medication’s alleged association with gynecomastia (male breast growth), has scheduled its next monthly meeting to discuss the progress of the litigation. According to court documents filed in the Philadelphia Court of Common Pleas, the meeting will be convened on Tuesday, June 16th, at 2:00 p.m. The parties are to meet in Courtroom 602 at Philadelphia City Hall. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is representing Risperdal plaintiffs who allegedly experienced excessive male breast development as a result of treatment with this medication. This meeting is likely to address topics relevant to these claims, such as issues surrounding discovery and any future trials,” said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide Risperdal lawsuit consultations to men and boys who allegedly developed gynecomastia due to their use of the medication.

Risperdal Litigation
Court documents indicate that just over 1,320 Risperdal lawsuits have been filed in the Pennsylvania mass tort program. These filings include numerous cases involving the drug’s alleged association with gynecomastia, a condition marked by excessive male breast development. In many of these claims, plaintiffs are alleged to have experienced breast growth severe enough to warrant mastectomy or other surgical intervention to remove excess breast tissue. Their lawsuits accuse Johnson & Johnson and its subsidiary Janssen Pharmaceuticals of concealing information about the drug’s effect on prolactin, a hormone that plays a role in female breast development and lactation.

Court records indicate that two Risperdal bellwether trials have concluded this year in the Pennsylvania litigation, both of which involved gynecomastia allegations. The first trial ended on February 24th, with the jury awarding $2.5 million to an autistic man who experienced excessive breast growth after taking Risperdal as a child. (Case No. A-196444) The second trial concluded on March 20th, with the jury finding that Johnson & Johnson and Janssen’s warnings about male breast growth were inadequate. However, the plaintiff was not awarded any monetary damages because the panel concluded that he had not proven that Risperdal caused his condition. (Case No. 130301803)

“These trials are extremely important, as they are intended to provide insight into how juries might rule in similar cases involving Risperdal and male breast growth. We look forward to the continuation of the Court’s bellwether trial program,” says Sandy A. Liebhard.

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website